Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan.

Annals of oncology : official journal of the European Society for Medical Oncology - 1 Aug 1998

Ando Y, Saka H, Asai G, Sugiura S, Shimokata K, Kamataki T

Abstract excerpt

BACKGROUND: Irinotecan (CPT-11) is metabolized by esterase to form a SN-38, which is further conjugated by UGT1A1. Genetic polymorphism has been shown in a promoter region of UGT1A1 and is related to its activity. We investigated whether there might be an inter-individual difference in pharmacokinetics of SN-38 and its glucuronide, depending on the genotypes of UGT1A1. PATIENTS AND METHODS: Nine male patients...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Antineoplastic Agents, Phytogenic

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Genotype

Share to Glucuronosyltransferase

Share to Lung Neoplasms

Share to Polymorphism, Genetic

Share to Promoter Regions, Genetic

Share to TATA Box

Source

Identifiers

PMID: 9789606
DOI: 10.1023/a:1008438109725

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan.PMID 9789606Read ↗

UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity.Semantic proximity Read ↗

Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism.Semantic proximity Read ↗

Association analysis of UGT1A genotype and haplotype with SN-38 glucuronidation in human livers.Semantic proximity Read ↗

Pharmacogenetic impact of polymorphisms in the coding region of the UGT1A1 gene on SN-38 glucuronidation in Japanese patients with cancer.Semantic proximity Read ↗

Polymorphisms of the UDP-glucuronosyl transferase 1A genes are associated with adverse events in cancer patients receiving irinotecan-based chemotherapy.Semantic proximity Read ↗

Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38), an active metabolite of irinotecan (CPT-11), by human UGT1A1 variants, G71R, P229Q, and Y486D.Semantic proximity Read ↗

Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28Semantic proximity Read ↗

Clinical Pharmacogenetics of Irinotecan (CPT-11)Semantic proximity Read ↗

Pharmacogenetics of Irinotecan Disposition and Toxicity: A ReviewSemantic proximity Read ↗

Distribution of the UGT1A1*28 polymorphism in Caucasian and Asian populations in the US: a genomic analysis of 138 healthy individuals.Semantic proximity Read ↗

Analysis of UGT1A1*28 genotype and SN-38 pharmacokinetics for irinotecan-based chemotherapy in patients with advanced colorectal cancer: results from a multicenter, retrospective study in Shanghai.Semantic proximity Read ↗

Pharmacokinetic and Pharmacogenetic Markers of Irinotecan Toxicity.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.